
Natera Investor Relations Material
Latest events

Q1 2025
Natera
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Natera Inc
Access all reports
Natera, Inc. develops and commercializes molecular testing services for reproductive health. It provides Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to analyze chromosomal anomalies or subchromosomal aberrations; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or subchromosomal aberrations; and Anora product platform, a single tube platform to detect cell-free DNA in maternal blood.
Key slides for Natera Inc


Q4 2024
Natera Inc


Q4 2024
Natera Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
NTRA
Country
🇺🇸 United States